by David Drake
Alzheimer’s Disease is a scourge that makes people forget their loved ones, closest family members, and even their most precious memories. They can lose track of seasons, dates and the passage of time, as well as forget where they are or how they arrived there. It has affected so far 5.4 million people in the US alone. That number should be zero.
If a treatment is not found soon, the number will almost triple to 13.8 million by 2050 in the US alone, according to the Alzheimer’s Association. The race to find its prevention and cure is therefore extremely important, as we see technological advances being made for other diseases that afflict the elderly like prostate cancer, rheumatoid arthritis, and Parkinson’s Disease. Who says what we can and can’t do to fight Alzheimer’s?
The pharmaceutical industry is not silent on this. In fact, fifteen years and billions of dollars from leading companies went down the drain for the research and production of 20 drugs aimed to cure Alzheimer’s Disease. These 20 drugs were not effective in treating the disease since 19 of them incorrectly targeted Beta Amyloid plaques in the brain as the culprit while one of them focused on Phosphorylated Tau (P-Tau) which is highly likely “non-toxic”.
Light at the End of the Tunnel: Fighting the Bad Tau
Recent results from several prestigious universities marked Acetylated Tau (Ac-Tau), now known as the BAD Tau, as the pathway to developing Alzheimer’s Disease. Ac-Tau is the toxin found in 100% of AD cases that is not found in healthy individuals. Phosphorylated Tau (P-Tau), the non-toxic one, is not bad and not associated with the AD pathway. P-Tau can be found in many normal individuals but is elevated in some Alzheimer’s Disease patients likely because of the presence of Ac-Tau.
The first drug aimed to prevent, delay the onset, and treat Alzheimer’s Disease (AD) is CogWellin™ and it might soon be in the market by 2020. The drug has a pending patent, and needs only one of three clinical trials to be successful after its manufacture and use by individuals with AD.
CogWellin™ is expected to very quickly as well as dramatically and significantly change the number of patients and deaths associated with Alzheimer’s disease (AD). This drug has the capacity to be the first and best to treat and prevent AD – the 6th leading cause of death for 65-year-olds and above in the US.
Dr. John W. Ludlow, Ph.D. of J.W.Ludlow Consulting, LLC, says “With November being Alzheimer’s Awareness Month, it seems appropriate to also bring awareness to the continuing efforts of CogWellin LLC to combat this devastating disease. With the tremendous strides being made in palliative care, the next breakthrough needs to come in the area of prognostic indication for patients demonstrating reduced cognitive abilities. CogWellin LLC is actively engaged in pursuing the utility of a protein marker found in spinal fluid which may very well be such a prognostic indicator. If the current experimental data continues to hold true, this will be the next big breakthrough in Alzheimer’s disease treatment.” It was his lab that discovered for the first time in the world that Ac-Tau is measurable in AD patients and not found in age-matched control non-cognitively impaired subjects.
Taking the AD Challenge since 1981
Dr. Joel Ross, MD, founder and owner of CogWellin LLC, is the man behind a series of tests aimed at reversing, slowing and preventing Alzheimer’s Disease. He started his research in 1981 and he has so far cared for more than 5000 AD patients. Since 1986, his main focus was to establish the root cause of AD.
Dr. Ross has already performed more than 125 clinical tests, collaborating with pharmaceutical companies around the world, in search for an effective AD treatment approach. From these tests, he found what has not worked and researched it extensively. This pointed him to the direction of the highly poisonous Acetylated Tau (Ac-Tau) which is present in all AD cases.
Ac-Tau is a toxic protein produced in the brain cells without which Dr. Ross feels no AD symptoms will occur. By removing it, the results can be earth-shattering in terms of millions of lives improved and millions of people avoiding or delaying the onset of AD even by decades.
A colleague in the pharmaceutical industry who goes by his initials B.I., a Ph.D. had this to say about Dr. Ross’ work with Alzheimer’s Disease, “ You are doing a great work, potentially useful for the entire Alzheimer community.”
Salsalate: The Power of Nature to Heal Alzheimer’s
A study published in September 2015 by the prestigious Gladstone Institute in San Francisco found that when salsalate immediate-release was given to mice induced with Ac-Tau, levels of Ac-Tau were reduced; brain damage and shrinkage were reversed, and cognitive function was restored.
The salsalate immediate-release form is very rarely, if ever, prescribed anymore for arthritis due to significant side effects. These side effects will be likely completely eliminated with Dr. Ross’s new and provisionally patented formulation of salsalate called CogWellin™, a once-daily, slow-release formulation of salsalate. Cogwellin will treat the true root cause of AD: Acetylated Tau (Ac-Tau), the BAD Tau.
The active ingredient in this new drug called CogWellin™ is salsalate (two molecules of salicylic acid) which was originally obtained from the bark of the Willow Tree (Salix) over 2500 years ago and used by Hippocrates, the Father of Medicine. The molecular mechanism of CogWellin™ action is quite simple: It acts to restore normal function of Tau on the microtubule.
According to published papers, and in agreement with Dr. Ross, it reverses the acetylation of Tau by inhibiting the pathologically overactive enzyme called p-300, an acetyltransferase, leading to restore Tau back to its normal physiological/safe levels in the brain. This means that it is suitable for AD patients and those at risk of being affected. This once-daily, long-acting drug releases salsalate slowly and continuously.
Investing in Cogwellin
So far, CogWellin™ development has been very successful and promising. In 2015, Dr. Ross received a provisional patent for the drug. Additional studies need to be conducted for the drug to be fully patented. To achieve this, a total investment of $155 million is required. These studies will be carried out in two phases.
The first and very crucial phase, proof-of-concept (POC), requires $5 million. The study will involve testing the drug on AD patients who have Ac-Tau measurable either in their blood or cerebrospinal fluid. The aim of the study is to prove that Cogwellin safely and effectively reduces Ac-Tau levels in AD patients and therefore is a suitable treatment for the disease. When the required financial support is secured, the study will commence in the second quarter of 2017 and end of the third quarter in the same year.
The second phase will proceed regardless of the results obtained in phase one. This phase encompasses three studies: Alzheimer’s symptoms are preventable (ASAP), Alzheimer’s symptoms are treatable (ASAT), and Alzheimer’s dementia is treatable (ADIT). Each of these studies will require investments of nearly $50 million. ASAP, a 36-month study aims to delay onset or prevent AD symptoms. The study will be conducted on 45-year-olds and above, with a family history of Alzheimer’s Disease and Ac-Tau in their cerebrospinal fluid and/or blood.
Individuals, 45 years old and above, with mild cognitive impairment (MCI) symptoms resulting from Alzheimer’s Disease, will be the participants in ASAT. Their cerebrospinal fluid and blood will be tested for the presence of Ac-Tau. The aim of this study will be to prove that Cogwellin can slow the progression of mild cognitive impairment (MCI) in AD patients.
ADIT will also be conducted on anyone 45 years and older suffering from mild to moderate dementia resulting from AD. The aim of this study is to prove that CogwellinTM can slow down the development of dementia in such AD patients who harbor Ac-Tau in their blood and/or cerebrospinal fluid.
Disrupting the Pharmaceutical Industry
Medical trials are very expensive, and the three studies would definitely cost close to $1 billion with all major pharmaceutical companies. However, Dr. Ross together with his team of physicians and patients in different parts of the U.S. have already been asked years ago to consider creating a database for such studies. They have thus been pre-identified to consider to volunteer to take part in these studies. Their willingness is very valuable and will also help the total cost of the studies remain relatively low. If any one of these studies are successful and completed on schedule, CogwellinTM could be on the market as early as 2020.
The pharmaceutical industry will add onto this new development, and companies will be coming up with their own versions of the AD cure. After the FDA required tests have been conducted, and Cogwellin patent is finally approved, then it is a matter of waiting to see how the drug will perform. Once Cogwellin succeeds in curing, delaying or preventing AD, then significantly less will be afflicted by the disease. Cogwellin will also open up opportunities to possibly cure other dementia-related disorders. This will stimulate research on its use for these disorders. Patent for the drug will expire after 20 years and this will open up the floodgates for other companies to manufacture similar or improved versions of the said drug.
“I Had Alzheimer’s Disease”
Nancy D. says, “My husband, Alex, was diagnosed with early-onset Alzheimer’s disease in 2012 at age 54. He was brilliant; a graduate of Cornell University, and entrepreneur of a successful software development company, SoftSolve, Inc., since 1990,” She further adds, “Dr. Ross was recommended to us by the Caring Heart Brain Institute in Manasquan, NJ where Alex’s PET scan revealed his ill fate. At the time of our Introduction, Dr. Ross offered us the opportunity to partake in a trial medication which, unfortunately, offered no hope in curing or slowing down the progression of this disease. Dr. Ross never gave up hope though. Well aware that nothing on the pharmaceutical market today will make a dent in this dreadful disease, his outside-the-box thinking supported us and gave us renewed hope. It is his tireless determination, understanding of this disease, and years of experience that will lead us to the answer we have all been waiting for; the cure that is due us; the hope that those we love with our whole hearts suffering from Alzheimer’s disease will be whole again. If anyone lives to make this happen, it is Dr. Ross.”
Coming up with the current formulation of CogwellinTM has taken Dr. Ross over 34 years. This shows his commitment to saving the global population from AD. His goal is to see the first of many millions of AD sufferers wear a banner across their chest that reads simply “I HAD ALZHEIMER’S DISEASE”.
Regina T., an 85-year old patient of Dr. Joel Ross for 15 years, has a mild cognitive disorder (MCD). According to her, “my cognitive skills are still intact but I know intuitively that MCD has progressed. What’s in store for me? Probably Early Alzheimer’s Disease.” She says further, “Dr. Ross’s current research needs the full support and passionate interest of all age groups. I refuse to have my life compromised by a disease that means a living death.”
This disease is not only causing deaths in the U.S. but in all parts of the world. Dr. Ross’s mission is to get this drug to the market as soon as possible. Having been in the medical field for over three decades, he clearly understands the sufferings of AD patients. He spent all these years researching the root cause of the disease and developing its solution. At this stage, Dr. Ross says, “I am calling upon investors to provide the financial support for these studies so that Cogwellin will be in the market by 2020. You would have helped saved millions of lives and left a legacy second to none”.
Within the first 5 years of its launch, Cogwellin is projected to generate $50 billion in sales. With CogwellinTM available well into 2025, the onset of Alzheimer’s Disease might be delayed by several years. In 2030, the number of individuals with Alzheimer’s Disease could be reduced to 5.8 million, and by 2035 around 40 percent or 4 million Americans may never show signs of the disease. By 2050, only 7.8 million of the estimated 13.5 million Americans might have Alzheimer’s Disease.
With Alzheimer’s Disease treatment well in the market in 2025, total costs of caring for AD patients will be reduced to $368 billion in 2030, generating over $83 billion savings. The savings in terms of care costs will be $367 billion by 2050.
For more inquiries on how to support and invest, visit Cogwellin.com or contact Dr. Joel Ross at firstname.lastname@example.org.